| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |




From the Department of Pathology,* University of Michigan Medical School, Ann Arbor, Michigan; the Department of Pathology and Laboratory Medicine,
Veterans Administration Ann Arbor Healthcare System, Ann Arbor, Michigan; and AnorMED Incorporated,
Langley, British Columbia, Canada
CXCR4 is a major receptor for CXCL12 and is known to participate in multiple physiological systems. The present study tested a second generation CXCR4 antagonist, AMD3465, for effects on highly defined models of Th1- and Th2-cell-mediated hypersensitivity-type pulmonary granuloma formation. Type-1 and type-2 granulomas were induced, respectively, by intravenous challenge of sensitized CBA/J mice with Mycobacteria bovis purified protein derivative- or Schistosoma mansoni egg antigen-coated beads. Before challenge, mice were implanted with osmotic pumps releasing AMD3465 at 5 µg/hour (6 mg/kg/day). Compared to vehicle, AMD3465 had minimal effect on type-1 inflammation or cytokine responses in draining lymph nodes, but the type-2 inflammation was significantly abrogated with reductions in lesion size and eosinophil content as well as abrogated interleukin (IL)-5, IL-10, and IL-13 cytokine production in draining lymph nodes. The biased effect of AMD3465 correlated with greater CXCR4 ligand expression in the type-2 model. Treatment during a primary response impaired lymph node IL-2 production after both Mycobacteria bovis purified protein derivative and Schistosoma mansoni egg antigen challenge indicating an unbiased effect during immune induction. In summary, CXCR4 blockade inhibited eosinophil recruitment during type-2 granuloma formation and interfered with primary and secondary T-cell activation events in lymphoid tissue, suggesting potential therapeutic application for chronic hypersensitivity diseases.
This article has been cited by other articles:
![]() |
E. S. Magalhaes, C. N. Paiva, H. S. P. Souza, A. S. Pyrrho, D. Mourao-Sa, R. T. Figueiredo, A. Vieira-de-Abreu, H. S. Dutra, M. S. Silveira, M. I. C. Gaspar-Elsas, et al. Macrophage migration inhibitory factor is critical to interleukin-5-driven eosinophilopoiesis and tissue eosinophilia triggered by Schistosoma mansoni infection FASEB J, April 1, 2009; 23(4): 1262 - 1271. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Bai, H. Hayasaka, M. Kobayashi, W. Li, Z. Guo, M. H. Jang, A. Kondo, B.-i. Choi, Y. Iwakura, and M. Miyasaka CXC Chemokine Ligand 12 Promotes CCR7-Dependent Naive T Cell Trafficking to Lymph Nodes and Peyer's Patches J. Immunol., February 1, 2009; 182(3): 1287 - 1295. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Y. Wong, V. Bodart, M. Metz, J. Labrecque, G. Bridger, and S. P. Fricker Comparison of the Potential Multiple Binding Modes of Bicyclam, Monocylam, and Noncyclam Small-Molecule CXC Chemokine Receptor 4 Inhibitors Mol. Pharmacol., December 1, 2008; 74(6): 1485 - 1495. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Freeman, V. R. Stolberg, B.-C. Chiu, N. W. Lukacs, S. L. Kunkel, and S. W. Chensue CCR4 Participation in Th Type 1 (Mycobacterial) and Th Type 2 (Schistosomal) Anamnestic Pulmonary Granulomatous Responses J. Immunol., September 15, 2006; 177(6): 4149 - 4158. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |